U.S. FDA recommends authorizing Pfizer vaccine for emergency use
The U.S. Food and Drug Administration (FDA) announced that
For the new crown vaccine developed by the German biotech company BioNTech, Pfizer will be authorized for emergency use.
If the authorization process goes smoothly, it is expected to open this month.
This vaccine is an RNA vaccine,
In the clinical trial, a total of 6 trial participants died,
The trial lasted for 11 months. As of the end of July, a total of 43,538 participants had received the vaccine, and the mortality rate was 1.378 per 10,000.
The Medical Regulatory Agency "Medicines and Medical Products Regulatory Agency" (MHRA) recommends that if you have a history of severe allergies in the past, this vaccine is not recommended.
Because many subjects had severe allergic symptoms, even medical staff had allergic reactions.
The allergic symptoms, severity and allergic groups caused by it have not been clarified.
The current number of confirmed cases in the United States is 15,386,600
298,400 deaths
Population is 329,227,800 people
The infection rate is 465 per 10,000
The chance of being infected and dying is 9 in 10,000
Compared with the death rate of the vaccine, it is 6.5 times different.
美国FDA建议授权辉瑞疫苗可紧急使用
美国食品药品监督管理局（FDA）宣布，
对于德国生技公司BioNTech所研发，辉瑞进行试验和商业化的新冠疫苗，将给予紧急使用的授权.
若授权过程顺利的话，预计本月开放施打。
这一款疫苗，是 RNA 疫苗，
在临床试验中，共有6名试验者死亡，
试验历时 11 个月，截止 7 月底共有 43,538 例参试者接种过此疫苗，死亡率为1万分之1.378。
医疗监管机构「药品暨医疗产品监管署」（MHRA）建议，若过去曾有过严重的过敏病史，不建议施打此疫苗。
因为有多名受试者引发了严重的过敏症状，甚至连医护人员也有人产生了过敏反应，
其引发的过敏症状、程度以及过敏族群尚未厘清。
目前美国的确诊数为15386600人
死亡数为298400人
人口为329227800人
感染率为1万分之465
受感染并死亡的机率为1万分之9
与施打疫苗的死亡率相比, 相差6.5倍